Vous avez cherché: resistance mutation (Anglais - Danois)

one resistance mutation was observed in each of 3 isolates:
14 af disse isolater blev genotypeanalyseret, hvoraf tre isolater havde mutationer med proteaseresistens.

a summary of resistance mutation development is shown in table 3.
et resumé over udviklingen af resistensmutation findes i tabel 3.

patients with resistance mutations (%)
patienter med resistensmutationer (%)

tipranavir resistance-associated mutations
mutationer i forbindelse med tipranavir-resistens

genotypic mutation pattern and cross-resistance
genotypemutationsmønster og krydsresistens

three of 14 isolates had protease resistance mutations.
14 af disse isolater blev genotypeanalyseret, hvoraf tre isolater havde mutationer med proteaseresistens.

number of saquinavir associated resistance mutations at baseline
antal baseline saquinavir- forbundne resistensmutatio ner*

resistance mutations tend to be viral sub-type specific.
resistensmutationer er ofte viralt subtype-specifikke.

genotypic and phenotypic evidence identified rtm204i, alone or in combination with rtl80i/v, as the key resistance mutation.
genotypiske og fænotypiske holdepunkter identificerede rtm204i, alene eller i kombination med rel80i/v, som den vigtigste resistensmutation.

only five had adefovir-associated resistance mutations at baseline.
kun fem patienter havde mutationer med relation til adefovirresistens ved baseline.

the currently available data both in vitro and in patients suggest that hbv expressing the adefovir- associated resistance mutation rtn236t is susceptible to lamivudine.
de nuværende tilgængelige data både in vitro og hos patienter tyder på, at hbv, som eksprimerer den adefovirforbundne resistensmutation rtn236t, er følsom over for lamivudin.

preliminary data, both in vitro and in patients, suggest the adefovir-associated resistance mutation rta181v may confer a reduced susceptibility to lamivudine.
foreløbige data både in vitro og hos patienter tyder på, at den adefovir-forbundne resistensmutation rta181v kan medføre nedsat følsomhed over for lamivudin.

cobicistat does not select any hiv resistance mutations, due to its lack of antiviral activity.
cobicistat selekterer ikke hiv-resistensmutationer pga. dets mangel på antiviral aktivitet.

12 resistance in vivo: in antiretroviral treatment naive patients, the i50l substitution, sometimes in combination with an a71v change, is the signature resistance mutation for atazanavir.
12 resistens in vivo:hos patienter, der ikke tidligere har modtaget antiretroviral behandling er i50l -substitutionen, nogle gange i kombination med a71v-ændring, den kendetegnende resistensmutation for atazanavir.

cross-resistance to protease inhibitor resistance mutations is not expected due to the different viral enzymes targeted.
krydsresistens over for proteasehæmmerresistensmutationer forventes ikke, da der sigtes mod forskellige virusenzymer.

virological response to saquinavir/ritonavir stratified by the number of baseline saquinavir- associated resistance mutations
virologisk respons af saquinavir/ ritonavir indelt efter antallet af baseline saquinavir - associerede resistensmutationer.

the number of key pi-resistance mutations increases markedly the longer a failing pi-containing regimen is continued.
antallet af mutationer, der har betydning for pi-resistens øges væsentligt, jo længere et regime med svigtende proteasehæmmere fortsættes.

all hiv-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir developed resistance mutations to both emtricitabine and elvitegravir.
alle hiv 1- isolater fra patienter i begge behandlingsgrupper, der udviklede resistensmutationer over for elvitegravir, udviklede også resistensmutationer over for både emtricitabin og elvitegravir.

all hiv-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in rt.
alle hiv 1-isolater fra patienter i begge behandlingsgrupper, der udviklede resistensmutationer over for elvitegravir i integrase, udviklede også resistensmutationer over for emtricitabin i rt.

the activity of tenofovir against hiv-1 strains with zidovudine-associated mutations appears to depend on the type and number of these resistance mutations.
tenofovirs aktivitet mod hiv-1-stammer med zidovudin-forbundne mutationer synes at afhænge af arten og antallet af disse resistensmutationer.